CA3217403A1 - Orexin receptor agonists and uses thereof - Google Patents
Orexin receptor agonists and uses thereof Download PDFInfo
- Publication number
- CA3217403A1 CA3217403A1 CA3217403A CA3217403A CA3217403A1 CA 3217403 A1 CA3217403 A1 CA 3217403A1 CA 3217403 A CA3217403 A CA 3217403A CA 3217403 A CA3217403 A CA 3217403A CA 3217403 A1 CA3217403 A1 CA 3217403A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- mmol
- cycloalkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183321P | 2021-05-03 | 2021-05-03 | |
| US63/183,321 | 2021-05-03 | ||
| PCT/EP2022/061851 WO2022233872A1 (en) | 2021-05-03 | 2022-05-03 | Orexin receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217403A1 true CA3217403A1 (en) | 2022-11-10 |
Family
ID=81940742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217403A Pending CA3217403A1 (en) | 2021-05-03 | 2022-05-03 | Orexin receptor agonists and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240254143A1 (https=) |
| EP (1) | EP4334323A1 (https=) |
| JP (1) | JP2024516033A (https=) |
| KR (1) | KR20240004802A (https=) |
| CN (1) | CN117616030A (https=) |
| AU (1) | AU2022269811A1 (https=) |
| BR (1) | BR112023022050A2 (https=) |
| CA (1) | CA3217403A1 (https=) |
| IL (1) | IL308099A (https=) |
| MX (1) | MX2023012971A (https=) |
| TW (1) | TW202309051A (https=) |
| WO (1) | WO2022233872A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| WO2023081094A1 (en) * | 2021-11-04 | 2023-05-11 | University Of Washington | Novel spirocyclic compounds as klhdc2 ligands |
| EP4658660A1 (en) | 2023-01-31 | 2025-12-10 | Jazz Pharmaceuticals Ireland Limited | Macrocyclic orexin receptor agonists and uses thereof |
| CN116478076A (zh) * | 2023-04-26 | 2023-07-25 | 南京优氟医药科技有限公司 | 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69318854T2 (de) * | 1993-03-04 | 1998-10-08 | Pfizer | Spiroazacyclischderivate als substanz p antagonisten |
| DE69923744T2 (de) * | 1998-10-23 | 2006-02-23 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten |
| WO2011076747A1 (en) * | 2009-12-21 | 2011-06-30 | Novartis Ag | Diaza-spiro[5.5]undecanes as orexin receptor antagonists |
| US20120101110A1 (en) * | 2010-10-26 | 2012-04-26 | Sangamesh Badiger | Diaza-spiro[5.5]undecanes |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| JP7413261B2 (ja) * | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US11098029B2 (en) * | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2022
- 2022-05-03 KR KR1020237041381A patent/KR20240004802A/ko active Pending
- 2022-05-03 MX MX2023012971A patent/MX2023012971A/es unknown
- 2022-05-03 CN CN202280045968.9A patent/CN117616030A/zh active Pending
- 2022-05-03 WO PCT/EP2022/061851 patent/WO2022233872A1/en not_active Ceased
- 2022-05-03 JP JP2023567888A patent/JP2024516033A/ja active Pending
- 2022-05-03 EP EP22727800.9A patent/EP4334323A1/en active Pending
- 2022-05-03 US US18/558,245 patent/US20240254143A1/en active Pending
- 2022-05-03 AU AU2022269811A patent/AU2022269811A1/en active Pending
- 2022-05-03 TW TW111116714A patent/TW202309051A/zh unknown
- 2022-05-03 IL IL308099A patent/IL308099A/en unknown
- 2022-05-03 CA CA3217403A patent/CA3217403A1/en active Pending
- 2022-05-03 BR BR112023022050A patent/BR112023022050A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012971A (es) | 2024-01-16 |
| JP2024516033A (ja) | 2024-04-11 |
| AU2022269811A1 (en) | 2023-11-16 |
| BR112023022050A2 (pt) | 2023-12-26 |
| US20240254143A1 (en) | 2024-08-01 |
| EP4334323A1 (en) | 2024-03-13 |
| CN117616030A (zh) | 2024-02-27 |
| KR20240004802A (ko) | 2024-01-11 |
| WO2022233872A1 (en) | 2022-11-10 |
| TW202309051A (zh) | 2023-03-01 |
| IL308099A (en) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3217403A1 (en) | Orexin receptor agonists and uses thereof | |
| JP7264810B2 (ja) | アルファｖインテグリン阻害剤としてのシクロブタン－およびアゼチジン－含有の単環およびスピロ環式化合物 | |
| AU2015371294B2 (en) | Compounds, compositions, and methods for increasing CFTR activity | |
| CA2993450C (en) | Compounds, compositions and methods of increasing cftr activity | |
| KR100794184B1 (ko) | 디펩티딜 펩티데이즈-ｉｖ(ｄｐｐ-ｉｖ) 저해용 신규화합물, 그것의 제조방법 및 그것을 활성성분으로서함유하는 약제 조성물 | |
| EP4284365A1 (en) | Cdk2 inhibitors and methods of using the same | |
| RS52175B (sr) | Hidroksimetil pirolidini kao agonisti beta 3 adrenergičkog receptora | |
| WO2021170631A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| EP4132650A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| KR20170047397A (ko) | 치환된 피페리딘 화합물 | |
| WO2021170627A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| EP2709984B1 (en) | New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds | |
| WO2024026479A2 (en) | Cdk2 inhibitors and methods of using the same | |
| JP2025538190A (ja) | Ｅｇｆｒキナーゼの分解のための化合物 | |
| US20250320227A1 (en) | Macrocyclic orexin receptor agonists and uses thereof | |
| WO2025245351A1 (en) | Substituted aryl sulfonamides and compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250407 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250407 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |